Extramedullary disease in multiple myeloma - controversies and future directions.

[1]  L. Tang,et al.  Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017 , 2018, Cancer Cell International.

[2]  N. Kröger,et al.  Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT , 2018, Haematologica.

[3]  S. Ševčíková,et al.  Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic , 2017 .

[4]  K. Kimura,et al.  Long non‐coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma , 2017, British journal of haematology.

[5]  Ravi Kumar,et al.  Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome , 2017, Bone Marrow Transplantation.

[6]  A. Minguela,et al.  Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement , 2017, Clinical case reports.

[7]  G. Morgan,et al.  Haematological cancer: Where are we now with the treatment of multiple myeloma? , 2017, Nature Reviews Clinical Oncology.

[8]  M. Dimopoulos,et al.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study , 2017, British journal of haematology.

[9]  S. Ševčíková,et al.  Deregulated expression of long non‐coding RNA UCA1 in multiple myeloma , 2017, European journal of haematology.

[10]  Michael L. Wang,et al.  Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. , 2016, Blood.

[11]  S. Ševčíková,et al.  Cytogenetics in multiple myeloma patients progressing into extramedullary disease , 2016, European journal of haematology.

[12]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[13]  M. Koudijs,et al.  Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses , 2016, Blood Cancer Journal.

[14]  A. Jakubowiak,et al.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial , 2016, The Lancet.

[15]  P. Moreau,et al.  How I treat extramedullary myeloma. , 2016, Blood.

[16]  F. Strozzi,et al.  Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma , 2016, Oncotarget.

[17]  J. Hrbek,et al.  Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. , 2016, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[18]  H. Goldschmidt,et al.  Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. , 2015, American journal of nuclear medicine and molecular imaging.

[19]  H. Goldschmidt,et al.  Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone , 2015, Haematologica.

[20]  S. Lonial,et al.  How I treat high-risk myeloma. , 2015, Blood.

[21]  S. Ševčíková,et al.  Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma , 2015, PloS one.

[22]  M. Chiarini,et al.  CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. , 2015, Cell reports.

[23]  N. Munshi,et al.  Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations , 2015, British journal of haematology.

[24]  L. Qiu,et al.  Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. , 2015, Clinical lymphoma, myeloma & leukemia.

[25]  B. Pégourié,et al.  Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. , 2015, Blood.

[26]  N. Munshi,et al.  Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation , 2014, British journal of haematology.

[27]  M. Boccadoro,et al.  Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients , 2014 .

[28]  L. Hrabálek,et al.  X-Ray in Multiple Myeloma - Not a ?Golden Standard? any More: Case Series , 2014 .

[29]  H. Goldschmidt,et al.  Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Barlogie,et al.  Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. , 2014, Clinical lymphoma, myeloma & leukemia.

[31]  N. Munshi,et al.  MRI features of extramedullary myeloma. , 2014, AJR. American journal of roentgenology.

[32]  B. Barlogie,et al.  Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. , 2014, The Lancet. Oncology.

[33]  S. Ševčíková,et al.  Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse , 2014, Haematologica.

[34]  S. Trudel,et al.  Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents , 2013, British journal of haematology.

[35]  I. Ghobrial,et al.  Extramedullary multiple myeloma , 2013, Leukemia & lymphoma.

[36]  M. Tiemann,et al.  Cytogenetics of extramedullary manifestations in multiple myeloma , 2013, British journal of haematology.

[37]  S. Ševčíková,et al.  Serum miR-29a as a marker of multiple myeloma , 2013, Leukemia & lymphoma.

[38]  B. Barlogie,et al.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data , 2013, Haematologica.

[39]  J. Bladé,et al.  Extramedullary involvement in multiple myeloma , 2012, Haematologica.

[40]  B. Barlogie,et al.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.

[41]  D. Rossi,et al.  Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients , 2012, Cancer.

[42]  E. Haralambieva,et al.  Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases , 2012, Annals of Hematology.

[43]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[44]  J. Bladé,et al.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Hernandez,et al.  Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma , 2011, European journal of haematology.

[46]  A. Dispenzieri,et al.  Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma , 2011, Leukemia.

[47]  B. Burwinkel,et al.  Characterization of extracellular circulating microRNA , 2011, Nucleic acids research.

[48]  J. Rivas,et al.  Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling , 2010, Leukemia.

[49]  C. Pascutto,et al.  Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[51]  M. Terol,et al.  Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)â/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial. , 2009 .

[52]  Hong Chang,et al.  p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. , 2009, Leukemia research.

[53]  E. Katodritou,et al.  Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? , 2009, Leukemia research.

[54]  M. Metzger,et al.  Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. , 2009, Leukemia research.

[55]  E Terpos,et al.  International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.

[56]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[57]  Aled Clayton,et al.  Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. , 2008, Journal of immunological methods.

[58]  M. Kersten,et al.  Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome , 2008, Bone Marrow Transplantation.

[59]  Charles P. Lin,et al.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. , 2007, Blood.

[60]  Piero Carninci,et al.  Noncoding RNA transcription beyond annotated genes. , 2007, Current opinion in genetics & development.

[61]  F. Fernández‐Avilés,et al.  Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients , 2006, Leukemia.

[62]  G. Ott,et al.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis , 2005, The Journal of pathology.

[63]  G. Tricot,et al.  Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features , 2004, Leukemia & lymphoma.

[64]  T. Rasmussen,et al.  Differential expression of CD56 and CD44 in the evolution 
of extramedullary myeloma , 2002, British journal of haematology.

[65]  K. Clausen,et al.  Liver disease in multiple myeloma. , 1973, Archives of internal medicine.

[66]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[67]  M. Cazzola,et al.  The possible role of burden of therapy on the risk of myeloma extramedullary spread , 2016, Annals of Hematology.

[68]  T. Buchler,et al.  Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients. , 2007, Neoplasma.

[69]  R. Fanin,et al.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.

[70]  S. Indraccolo,et al.  The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. , 2006, Haematologica.

[71]  J. Esteve,et al.  Extramedullary multiple myeloma escapes the effect of thalidomide. , 2004, Haematologica.

[72]  L. Cro,et al.  p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. , 1993, Blood.

[73]  F. J. Heck,et al.  Extramedullary lesions in multiple myeloma; review of literature and pathologic studies. , 1952, A.M.A. archives of pathology.